“Reviewing this information will settle the ongoing public debate regarding the adequacy of the FDA’s review process,” adds the suit. “Releasing this data should also confirm the FDA’s conclusion that the Pfizer Vaccine is safe and effective and, thus, increase confidence in the Pfizer Vaccine.”